ASLAN Pharmaceuticals Ltd ADR (ASLN): A Technical Analysis

ASLN has 36-month beta value of 1.47. Analysts have mixed views on the stock, with 2 analysts rating it as a “buy,” 1 as “overweight,” 1 as “hold,” and 0 as “sell.”

The public float for ASLN is 16.09M, and currently, short sellers hold a 1.81% ratio of that float. The average trading volume of ASLN on April 04, 2024 was 1.01M shares.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

ASLN) stock’s latest price update

The stock price of ASLAN Pharmaceuticals Ltd ADR (NASDAQ: ASLN) has dropped by -6.91 compared to previous close of 0.57. Despite this, the company has seen a fall of -16.44% in its stock price over the last five trading days. GlobeNewsWire reported 2024-03-27 that SAN MATEO, Calif. and SINGAPORE, March 27, 2024 (GLOBE NEWSWIRE) — ASLAN Pharmaceutical (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that management will give a virtual company presentation at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and Disorders, to be held virtually on Thursday, March 28, 2024. ASLAN management will also be available for one-on-one meetings with investors on the day of the conference. Please register for the event via this link or contact your representative at H.C. Wainright to schedule a meeting.

ASLN’s Market Performance

ASLAN Pharmaceuticals Ltd ADR (ASLN) has seen a -16.44% fall in stock performance for the week, with a -17.74% decline in the past month and a -3.53% plunge in the past quarter. The volatility ratio for the week is 10.80%, and the volatility levels for the past 30 days are at 34.70% for ASLN. The simple moving average for the past 20 days is -24.88% for ASLN’s stock, with a -62.72% simple moving average for the past 200 days.

Analysts’ Opinion of ASLN

Many brokerage firms have already submitted their reports for ASLN stocks, with Jefferies repeating the rating for ASLN by listing it as a “Buy.” The predicted price for ASLN in the upcoming period, according to Jefferies is $8 based on the research report published on July 09, 2021 of the previous year 2021.

H.C. Wainwright, on the other hand, stated in their research note that they expect to see ASLN reach a price target of $8.50, previously predicting the price at $12. The rating they have provided for ASLN stocks is “Buy” according to the report published on January 14th, 2019.

ASLN Trading at -15.42% from the 50-Day Moving Average

After a stumble in the market that brought ASLN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -88.69% of loss for the given period.

Volatility was left at 34.70%, however, over the last 30 days, the volatility rate increased by 10.80%, as shares sank -8.77% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -2.70% lower at present.

During the last 5 trading sessions, ASLN fell by -16.44%, which changed the moving average for the period of 200-days by -86.70% in comparison to the 20-day moving average, which settled at $0.7038. In addition, ASLAN Pharmaceuticals Ltd ADR saw 1.63% in overturn over a single year, with a tendency to cut further gains.

Stock Fundamentals for ASLN

Current profitability levels for the company are sitting at:

  • -3.69 for the present operating margin
  • 1.0 for the gross margin

The net margin for ASLAN Pharmaceuticals Ltd ADR stands at -3.77. The total capital return value is set at -1.87. Equity return is now at value -426.46, with -77.05 for asset returns.

Based on ASLAN Pharmaceuticals Ltd ADR (ASLN), the company’s capital structure generated 1.02 points at debt to capital in total, while cash flow to debt ratio is standing at -0.16. The debt to equity ratio resting at -43.47. The interest coverage ratio of the stock is -10.77.

Currently, EBITDA for the company is -47.61 million with net debt to EBITDA at 0.06. When we switch over and look at the enterprise to sales, we see a ratio of 0.57. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.11.

Conclusion

To put it simply, ASLAN Pharmaceuticals Ltd ADR (ASLN) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts